Placental proteins in oncology.

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Placental proteins are frequently detected in serum and tumors of cancer patients.
• Few placental proteins have established roles in clinical cancer management.
• Chorionic gonadotropin (hCG) is a validated marker for trophoblastic disease.

Purpose of the Study:

• To review the clinical utility of various placental proteins as cancer biomarkers.
• To assess their role in monitoring treatment and detecting recurrent disease.
• To evaluate their potential for cancer screening in asymptomatic populations.

Main Methods:

• Review of existing literature on placental proteins and their association with malignant diseases.
• Analysis of the established clinical applications of specific markers like hCG and placental alkaline phosphatase (PLAP).
• Evaluation of the diagnostic and prognostic value of PP series proteins and PLAP isoenzymes.

Main Results:

• Human chorionic gonadotropin (hCG) is effective for trophoblastic disease and can indicate recurrent germ cell tumors.
• Placental alkaline phosphatase (PLAP) isoenzymes are secreted by seminomas and dysgerminomas, aiding treatment monitoring in some centers.
• Placental proteins (PP) series offer insights into tumor biology but lack proven clinical importance.
• No discussed placental protein markers are suitable for screening cancer in healthy individuals.

Conclusions:

• Established placental protein markers like hCG and PLAP are valuable for monitoring specific cancers and detecting recurrence.
• Emerging markers like the PP series require further research to establish clinical significance.
• Current placental protein markers are not effective for general cancer screening in asymptomatic populations.